|
News for Healthier Living
New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups
Caris Life Sciences(r) (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients.
August 13, 2025
August 15 2025August 14 2025August 13 2025August 12 2025August 11 2025August 10 2025August 9 2025August 8 2025August 7 2025August 6 2025August 5 2025August 4 2025August 3 2025August 2 2025
|
|
|
|
|